

pureScientific  
technologies

**PURE SCIENTIFIC TECHNOLOGIES INC.**

*“ Striving to make medicine work better for you...”*

# FORWARD LOOKING STATEMENTS

This presentation may contain forward-looking statements relating to the future performance of Pure Scientific Technologies Inc. (“PST”). Forward-looking statements, specifically those concerning future performance and the achievement of operating profitability are subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties include the market acceptance of PST's products and services; competition within the medical technology industry and the introduction of new entrants and/or products in PST’s markets; adverse changes in governmental regulations and policies affecting the medical technology industry; product development risks and risks of technological change; the risk of unanticipated expenses; and other risks and uncertainties all as described in PST’s business plan and offering documents. Readers are cautioned that the foregoing list of factors is not exhaustive. Although PST believes that the expectations conveyed by the forward-looking statements are reasonable based on information available to it on the date such forward-looking statements are made, no assurances can be given as to future results, levels of activity and achievements. All subsequent forward-looking statements, whether written or oral, attributable to PST or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. PST assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.




# MISSION

To develop and market innovative products based on its patented technology utilizing Heliox and other gases for delivery of pharmaceuticals and CBD directly into the lungs.



# CORPORATE STRATEGY




- A development stage medical device company in Irvine, CA
- Ongoing focus on patentable drug delivery systems for pharmaceuticals and CBD
- Initial product nearing commercialization
- User-friendly inhaler with Heliox as carrier gas
- Studies have shown that Heliox is more effective than air at reaching target cells and distal regions of the lungs
- Digitally measured dosage and pressure control
- A timely solution with broad applications for pulmonary conditions
- Experienced management team proven successful in pioneering development of medical products for prostate cancer



# BENEFITS OF HELIOX

- FDA-approved breathing gas, non-toxic, non-carcinogenic with history of critical care use for decades
- Comprised of Helium (He) and Oxygen (O<sub>2</sub>) typically in a ratio of 80:20 or 70:30
- Small helium atom makes Heliox less dense than pure oxygen or air and therefore more easily absorbed into the bloodstream via the lungs
- Commercially available at relatively low cost
- An example: During acute asthma exacerbations, albuterol nebulized with Heliox (Left) leads to more significant improvement in spirometry compared with albuterol nebulized with oxygen (Right) because the lower-density Heliox improves albuterol deposition in the distal airways





Because of the very low density of helium, there is better delivery of albuterol nebulized with Heliox (Left) compared with albuterol Nebulized with oxygen (Right) in the lungs.

# EXISTING TECHNOLOGY

Heliox Therapy has been used in critical care situations historically to decrease the work of breathing, often in patients with airway obstructions or severe pulmonary distress.



Existing Heliox delivery systems are typically in the form of continuous ventilator devices that utilize constant flow of Heliox at low pressure from large tanks.

- The patient interface and Heliox components are assembled in a very complex delivery system
- Bulky and difficult to transport with large Heliox tanks
- Usage limited to hospitals and critical care facilities
- Labor intensive requiring continual oversight by medical professionals
- Requiring extended periods for delivery of drugs and treatment
- Expensive and less efficient use of Heliox



# PRODUCT OVERVIEW


- PST Helios Inhaler
- Potential for more efficient delivery of FDA- approved pharmaceuticals and CBD into the lungs and bloodstream
- Uses Heliox as the carrier gas in a closed loop system, on a per “puff” basis, thereby eliminating continuous gas flow offering efficient use of Helios.
- US Patent for “Dual Metered Inhaler” awarded March 5, 2024 (USPTO #: US11918735B2)
- Comfortable respiratory treatment experience
- ✓ Bluetooth connection to smartphone app including:
  - ✓ Secure Data Storage on dosage, flow measurement, pressure, time and date of treatment
  - ✓ Secure access by patient, caregiver and physician



*PST Helios Inhaler showing the portable base unit, containing the Heliox bottle and LED display interface providing historical and current user data. The handheld unit, attached with the Heliox line, with activation button for CBD aerosol and controlled flow of Heliox to deliver both ingredients on a per “puff” basis. The handheld unit also shows the CBD reservoir and mouthpiece.*




# CBD Device Components





# BENEFITS OF PST'S NEW HELIOX INHALER

The **PST HELIOS INHALER** utilizes a closed loop system with **digital dosing controls** that coordinate delivery of the pharmaceutical compound and Heliox from an internal aerosolization unit in controlled “puffs” upon initiation of inhalation.



Compared to continuous ventilator equipment devices, the PST Helios Inhaler is:

- ✓ Simple, small footprint and transportable
- ✓ Fit for use at home, in hospitals and other medical offices and facilities
- ✓ User-friendly with patients capable of self-administering prescribed medications
- ✓ Less labor intensive
- ✓ More economical and efficient in use of Heliox gas
- ✓ Potential to offer a much shorter period for delivery of medications.




Helios: PST Heliox Inhaler Unit in the home

**BOTTOM LINE: The PST HELIOS INHALER is designed to be a low-cost, safe and effective, user-friendly delivery platform for CBD and pharmaceuticals**

# DEVELOPMENT STRATEGY

Two parallel development pathways focused on implementing patentable technologies:



- ✓ The rapidly growing holistic cannabidiol (CBD) market, projected to hit \$16 Billion in the U.S. by 2025; inhaling is most effective way of obtaining CBD. \*
  - ✓ The growing market for treatment of lung diseases using FDA-approved pharmaceuticals, including asthma, chronic bronchitis, COPD, cancer and pulmonary pandemics
- Initial thrust is the commercialization of a desktop Heliox inhaler for the CBD market. Trade name “HELIOS”, it is a user-friendly device for use at home or in office
  - For use with readily available CBD from hemp
  - CBD market offers great potential for near-term financial returns with minimal regulatory oversight
  - Design and development knowledge gained from the CBD devices will be leveraged into new products for FDA-approved pharmaceuticals



\* New York-based investment bank [Cowen](#) & Co. released a study on the CBD (cannabidiol) market.

# REGULATORY PATHWAY

- The U.S. Food and Drug Administration (“FDA”) provides regulatory oversight and approval of new pharmaceuticals and medical devices
- Heliox is already approved for human use; natural occurring holistic compounds like CBD do not generally require FDA approval
- Fusing two FDA approved products (Heliox and approved pharmaceuticals) eases approval pathway
- Potential application of FDA Section 510(k) could streamline approval process for the use of the PST Heliox inhaler
- Management team has experience with the FDA approval process, having successfully obtained approval for a number of devices in less than one year from initial filing
- Efforts underway to identify and partner with researchers in academia, industry and public and private health





# ALLIANCE WITH NECTAR, INC.

- Nectar is a highly experienced interdisciplinary design, engineering and product development firm in Long Beach, CA
- 30 year history of successful development of ISO 13485 certified products with focus on medical devices
- Client base includes many industry leaders & well-known companies
- PST engaged Nectar to bring its highly skilled professional team to collaborate with PST in creation, development, engineering & production of its initial products
- Assures quality control and first tier development and engineering of PST's products



ISO 13485:2016  
DEVICE DEVELOPMENT

## Nectar streamlines the process.

From conception to design, our multi-fledged design and development team is on hand to support you through any obstacles effortlessly.



### ISO certification

Our streamlined, ISO-compliant processes help guide your product from concept to regulatory approval & commercialization with ease and speed.



### Commercialization delays


Our 30+ years of industry experience enable us to assist with any matter in question, including avoiding costly delay traps & inefficiencies that could derail the launch of your device or software.



### Unique development approach

Our rich history of bringing 1000+ devices to the market means we can help you get your product designed and market-ready all whilst reducing unnecessary costs, like those associated with rework.

# PURE SCIENTIFIC TECHNOLOGIES INC.




## PHASE 1 DEVELOPMENT COMPLETED

Incorporated April 29, 2020 under the laws of Nevada, PST has now completed its Phase 1 Development Program. This Phase comprised: (i) corporate organization;(ii) assembly of management team;(iii) raise of seed financing of \$508,000; (iv) filing of patent applications covering PST's technology; and (v) completion of a working prototype of PST's Helios inhaler with successful laboratory testing as proof of concept.

## PHASE 2 DEVELOPMENT & ENGINEERING COMPLETED

PST has now concluded its Phase 2 Development Program, comprising testing, further development and engineering, marketing studies and preparation for commercial launch of the CBD inhaler. In addition, further patent applications were filed covering PST's technology, additions were made to our management team and U.S.\$2.0 Million was raised in a private placement which closed in September 2021.




### **Videos:**

[Device GUI Demo](#)

[Mobile App Demo](#)

[Device Functional Demo](#)

# Pure Scientific Technologies Team



**L. MICHAEL CUTRER**

**CEO, PRESIDENT & DIRECTOR**

Mike Cutrer is a highly accomplished executive with extensive management and technical experience in the medical device field.

He was co-founder and served for eighteen years as President, CEO and a Director of North American Scientific, Inc. ("NASI") (a NASDAQ company), a Los Angeles-based manufacturer of radioisotope products for the medical industry.

NASI was an early innovator that successfully developed and marketed brachytherapy seeds implanted for the treatment of prostate cancer.



**IRWIN A. OLIAN**

**DIRECTOR**

Irwin Olian is a highly successful entrepreneur with a strong legal and finance background. He is a creative innovator and proven business leader.

Over the past thirty years, he has leveraged his skills in strategic business planning, management, administration, finance and law with creative thought and innovation to provide leadership to a large number of emerging companies.

He has broad experience in fields ranging from medical devices to biotechnology to high technology to entertainment to mining. His activities have included serving as the CEO or member of senior management or a director of a number of public and private companies, acting as a senior business consultant and being a strategic, early-stage investor.



**PHILIP CACAYORIN**

**VP - TECHNOLOGY**

Philip Cacayorin, serving as Vice President - Technology, brings his exceptional advanced mathematics, physics and computer engineering skills to bear on development, fabrication and marketing of our new line of products utilizing the Company's patent pending infusion technologies employing Heliox and helium as integral components of delivery systems for CBD and various pharmaceuticals directly into the lungs.



**HENRY CHOW, CPA, C.A.**


**CHIEF FINANCIAL OFFICER**

Henry has over 20 years' experience in financial and accounting matters for private and public companies, including mergers and acquisitions, IPO's and other financings as well as regulatory reporting and filings in both Canada and the U.S. He is familiar with both U.S. and Canadian accounting standards and has extensive audit experience.

Henry is a founding partner of Vancouver-based Saturna Group Chartered Professional Accountants LLP and remains active with that firm. In addition, he presently serves as CFO of California-based MedTech company Pure Scientific Technologies Inc. He is a graduate of the University of British Columbia with a Bachelor of Commerce Degree with Honours.



# Pure Scientific Technologies Team



**MARY BALDAUF M.D.**

**OUTSIDE DIRECTOR**

Dr. Mary Baldauf has been practicing Medicine for 26 years. Her specialty is Pediatric Critical Care Medicine. As a physician working in an Intensive Care Unit, Dr. Baldauf uses highly developed technologies such as Nitric Oxide and Heliox in the treatment of critically ill patients. She has extensive experience in the areas of mechanical ventilation and advanced airway management.

As the founder of a medical technology company, Dr. Baldauf was granted patents for a variety of devices, including congenital heart defect models, therapeutic cushioning and devices for assisting respiration and administering fluid to patients. As a dedicated physician, Dr. Baldauf remains committed to furthering patient care through emerging technologies.

Dr. Baldauf received her undergraduate degree in Biology from Harvard University. She holds a Master of Science in Applied Human Physiology from the University of Health Sciences / Chicago Medical School. Dr. Baldauf earned her Doctor of Medicine degree at the State University of New York.




**MARTIN A. URBAN M.D., MMM**

**OUTSIDE DIRECTOR**

Dr. Martin Urban is a highly experienced radiologist with extensive management and entrepreneurial skills, whose 30-year career covers the full range of interventional radiology, computed tomography and ultrasound.

In addition to his clinical experience, Marty brings 25 years management experience in the healthcare field, including ownership and management of a full-service freestanding imaging center and private practice radiology group. He has overseen patent filing and management and has a number of patents to his credit. He presently serves as Chairman of the Dept. of Medical Imaging at two hospitals in Illinois.

Marty received his Doctor of Medicine from Northwestern University Medical School and his Master of Medical Management from the University of Southern California. He has served as a Director of PST since March 2020.




**LEE DUNSTON**

**DIRECTOR OF CORPORATE COMMUNICATIONS**

Lee has thirty-five years experience in sales and marketing, IT, management, business development and investor relations. His focus will be communicating the PST story to the investment community.

His sales, marketing and business development experience includes working with several Enterprise Resource Planning software and healthcare management technology companies as well as business development, corporate communications and investor relations with several public startup companies.



pureScientific  
technologies

*“ Striving to make medicine work better for you...”*

# THANK YOU

---



info@purescientifictech.com



<https://www.purescientifictech.com>

Pure Scientific Technologies Inc.  
Michael Cutrer  
[mcutrer@purescientifictech.com](mailto:mcutrer@purescientifictech.com)